87 related articles for article (PubMed ID: 11126866)
1. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
2. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
3. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
5. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
6. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
7. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
9. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
10. Activity, stereospecificity, and stereoselectivity of microsomal enzymes in dependence on storage and freezing of rat liver samples.
Skálová L; Szotáková B; Wsól V; Král R; Baliharová V; Lamka J
Chirality; 2000 Oct; 12(9):649-53. PubMed ID: 10984737
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
Szotáková B; Skálová L; Wsól V; Kvasniècková E
J Pharm Pharmacol; 2000 May; 52(5):495-500. PubMed ID: 10864136
[TBL] [Abstract][Full Text] [Related]
12. Stereospecificity of flobufen metabolism in guinea pigs in vitro and in vivo: phase I of biotransformation.
Kral R; Skalova L; Szotakova B; Babu YN; Wsol V
Chirality; 2004 Jan; 16(1):1-9. PubMed ID: 14628293
[TBL] [Abstract][Full Text] [Related]
13. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
14. Central composite design as a powerful optimisation technique for enantioresolution of the rac-11-dihydrooracin--the principal metabolite of the potential cytostatic drug oracin.
Wsól V; Fell AF
J Biochem Biophys Methods; 2002 Dec; 54(1-3):377-90. PubMed ID: 12543513
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of flobufen enantiomers in ruminant hepatocytes and subcellular fractions.
Skálová L; Szotáková B; Lamka J; Král R; Vanková I; Baliharová V; Wsól V
Chirality; 2001; 13(10):760-4. PubMed ID: 11746816
[TBL] [Abstract][Full Text] [Related]
16. Stereospecificity and stereoselectivity of flobufen metabolic profile in male rats in vitro and in vivo: phase I of biotransformation.
Wsól V; Král R; Skálová L; Szotáková B; Trejtnar F; Flieger M
Chirality; 2001; 13(10):754-9. PubMed ID: 11746815
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier.
Andrýs R; Zemanová L; Lenčo J; Bílková Z; Wsól V
Chem Biol Interact; 2015 Jun; 234():169-77. PubMed ID: 25595226
[TBL] [Abstract][Full Text] [Related]
18. Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species.
Kucera R; Nobilis M; Skálová L; Szotáková B; Císar P; Jira T; Klimes J; Wsól V
J Pharm Biomed Anal; 2005 Apr; 37(5):1049-57. PubMed ID: 15862685
[TBL] [Abstract][Full Text] [Related]
19. Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist.
Karanam BV; Welch CJ; Reddy VG; Chilenski J; Biba M; Vincent S
Drug Metab Dispos; 2004 Oct; 32(10):1061-8. PubMed ID: 15229170
[TBL] [Abstract][Full Text] [Related]
20. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand.
Skarydová L; Andrýs R; Holubová L; Stambergová H; Kňavová J; Wsól V; Bílková Z
J Sep Sci; 2013 Apr; 36(7):1176-84. PubMed ID: 23495195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
